Executive Summary
Lupin's US subsidiary has received final US FDA approval of its ANDA for famotidine for oral suspension (40mg/5ml), a generic version of Merck & Co's H2-antagonist anti-ulcer product Pepcid for oral suspension. Pepcid is used for the short-term treatment of active duodenal ulcer, active benign gastric ulcer and gastro-oesophageal reflux disease. Lupin said that it had commenced shipments of its generic product. Pepcid for oral suspension had sales of about $29 million for the 12 months ended March 2010, according to IMS Health data cited by Lupin.